

DAFTAR PUSTAKA

- Aria, M., & Cuccurullo, C. (2017). *bibliometrix: An R-tool for comprehensive science mapping analysis*. *Journal of Informetrics*, 11(4), 959–975. <https://doi.org/10.1016/j.joi.2017.08.007>
- Aria, M., & Cuccurullo, C. (2020). *Biblioshiny: Bibliometrix for scientists*. R Package Bibliometrix Documentation.
- Bornmann, L., & Daniel, H. D. (2008). What do citation counts measure? A review of studies on citing behavior. *Journal of Documentation*, 64(1), 45–80. <https://doi.org/10.1108/00220410810844150>
- Cai, Z., Wang, S., Li, J., et al. (2021). Global trends in inflammatory bowel disease research: A bibliometric analysis. *Frontiers in Medicine*, 8, 775591. <https://doi.org/10.3389/fmed.2021.775591>
- Dimensions. (2024). *Dimensions Database*. <https://www.dimensions.ai>
- Donthu, N., Kumar, S., Mukherjee, D., Pandey, N., & Lim, W. M. (2021). How to conduct a bibliometric analysis: An overview and guidelines. *Journal of Business Research*, 133, 285–296. <https://doi.org/10.1016/j.jbusres.2021.04.070>
- Feagan, B. G., Sandborn, W. J., Danese, S., et al. (2024). Advances in inflammatory bowel disease treatment and clinical research. *The Lancet Gastroenterology & Hepatology*.
- Islam, M. M., Rahman, M. M., et al. (2024). Bradford's law application in biomedical bibliometric studies: A systematic review. *Scientometrics*.
- Kaplan, G. G., & Windsor, J. W. (2021). The four epidemiological stages in the global evolution of inflammatory bowel disease. *Nature Reviews Gastroenterology & Hepatology*, 18(1), 56–66. <https://doi.org/10.1038/s41575-020-00360-x>
- Lens. (2024). *The Lens*. <https://www.lens.org>
- Li, X., Wang, Y., Zhang, H., et al. (2022). Bibliometric analysis of global research trends in inflammatory bowel disease. *Frontiers in Medicine*, 9, 905674.
- Liu, Y., Zhang, J., Wang, X., et al. (2022). Immune dysregulation and gut microbiota in inflammatory bowel disease. *Frontiers in Immunology*, 13, 865476.
- Liu, Y., Zhang, J., Wang, X., et al. (2024). Recent advances in inflammatory bowel disease research: A bibliometric perspective. *Frontiers in Medicine*.
- National Center for Biotechnology Information. (2023). *PubMed Overview*. <https://pubmed.ncbi.nlm.nih.gov>

- Nakase, H., Uchino, M., Shinzaki, S., et al. (2021). Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. *Journal of Gastroenterology*, 56(6), 489–526. <https://doi.org/10.1007/s00535-021-01784-1>
- Öztürk, O., Yıldırım, M., & Kaya, A. (2024). Bibliometric analysis in medical research: Trends and applications. *Scientometrics*.
- Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ*, 372, n71. <https://doi.org/10.1136/bmj.n71>
- Passas, N. (2024). Citation analysis and research impact assessment in bibliometric studies. *Scientometrics*.
- Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2023). ACG clinical guideline: Ulcerative colitis in adults. *American Journal of Gastroenterology*.
- Stange, E. F. (2022). Future directions in inflammatory bowel disease research. *United European Gastroenterology Journal*.
- Torres, J., Bonovas, S., Doherty, G., et al. (2020). ECCO guidelines on therapeutics in Crohn's disease. *Journal of Crohn's and Colitis*.
- Torres, J., Bonovas, S., Doherty, G., et al. (2023). ECCO guidelines on therapeutics in Crohn's disease: Medical treatment. *Journal of Crohn's and Colitis*, 17(1), 3–45.
- Tsay, M. Y. (2005). Bradford's law of scattering and its applications. *Journal of Documentation*, 61(3), 364–381.
- Ungaro, R., Mehandru, S., Allen, P. B., Peyrin-Biroulet, L., & Colombel, J. F. (2017). Ulcerative colitis. *The Lancet*, 389(10080), 1756–1770. [https://doi.org/10.1016/S0140-6736\(16\)32126-2](https://doi.org/10.1016/S0140-6736(16)32126-2)
- Wahyudi, A., & Junaedi, D. (2023). Application of Lotka's law in bibliometric analysis of scientific publications. *Indonesian Journal of Information Studies*.
- Xu, F., Li, H., Wang, Z., et al. (2024). Artificial intelligence and precision medicine in inflammatory bowel disease. *Journal of Translational Medicine*.
- Zhang, A., Li, X., Wang, Y., et al. (2023). Current advances in inflammatory bowel disease: Gut microbiota, precision medicine, and biological therapy. *Frontiers in Medicine*, 10, 1182345.
- Ordás, I., Eckmann, L., Talamini, M., Baumgart, D. C., & Sandborn, W. J. (2012). Ulcerative colitis. *The Lancet*, 380(9853), 1606–1619. [https://doi.org/10.1016/S0140-6736\(12\)60150-0](https://doi.org/10.1016/S0140-6736(12)60150-0)

- Baumgart, D. C., & Sandborn, W. J. (2012). Crohn's disease. *The Lancet*, 380(9853), 1590–1605. [https://doi.org/10.1016/S0140-6736\(12\)60026-9](https://doi.org/10.1016/S0140-6736(12)60026-9)
- Nakase, H., Uchino, M., Shinzaki, S., et al. (2021). Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. *Journal of Gastroenterology*, 56(6), 489–526. <https://doi.org/10.1007/s00535-021-01784-1>
- Ng, S. C., Shi, H. Y., Hamidi, N., et al. (2017). Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century. *The Lancet*, 390(10114), 2769–2778. [https://doi.org/10.1016/S0140-6736\(17\)32448-0](https://doi.org/10.1016/S0140-6736(17)32448-0)
- Ananthakrishnan, A. N. (2015). Epidemiology and risk factors for inflammatory bowel disease. *Nature Reviews Gastroenterology & Hepatology*, 12(4), 205–217. <https://doi.org/10.1038/nrgastro.2015.34>
- Colombel, J. F., Narula, N., & Peyrin-Biroulet, L. (2017). Management strategies to improve outcomes of patients with inflammatory bowel diseases. *Gastroenterology*, 152(2), 351–361. <https://doi.org/10.1053/j.gastro.2016.09.046>
- Sandborn, W. J., Feagan, B. G., Hanauer, S. B., et al. (2002). A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. *Gastroenterology*, 122(2), 512–530.
- Peyrin-Biroulet, L., Loftus, E. V., Colombel, J. F., & Sandborn, W. J. (2010). The natural history of adult Crohn's disease in population-based cohorts. *The American Journal of Gastroenterology*, 105(2), 289–297. <https://doi.org/10.1038/ajg.2009.579>
- Roda, G., Chien Ng, S., Kotze, P. G., et al. (2020). Crohn's disease. *Nature Reviews Disease Primers*, 6(1), 22. <https://doi.org/10.1038/s41572-020-0156-2>
- Torres, J., Mehandru, S., Colombel, J. F., & Peyrin-Biroulet, L. (2017). Crohn's disease. *The Lancet*, 389(10080), 1741–1755. [https://doi.org/10.1016/S0140-6736\(16\)31711-1](https://doi.org/10.1016/S0140-6736(16)31711-1)
- Feuerstein, J. D., Ho, E. Y., Shmidt, E., et al. (2020). AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. *Gastroenterology*, 158(5), 1450–1461. <https://doi.org/10.1053/j.gastro.2020.01.006>
- Danese, S., Vermeire, S., Hellstern, P., et al. (2019). Randomised trial and open-label extension study of an oral Janus kinase inhibitor in ulcerative colitis. *The Lancet Gastroenterology & Hepatology*.
- Sandborn, W. J., Feagan, B. G., D'Haens, G., et al. (2022). Safety and efficacy of advanced therapies for inflammatory bowel disease. *The Lancet Gastroenterology & Hepatology*.

- Kobayashi, T., Siegmund, B., Le Berre, C., et al. (2020). Ulcerative colitis. *Nature Reviews Disease Primers*, 6(1), 74. <https://doi.org/10.1038/s41572-020-0205-x>
- Graham, D. Y., Lu, H., & Yamaoka, Y. (2007). A report card to grade *Helicobacter pylori* therapy. *Helicobacter*, 12(4), 275–278.
- Colombel, J. F., D'haens, G., Lee, W. J., Petersson, J., & Panaccione, R. (2020). Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease. *Journal of Crohn's and Colitis*.
- Louis, E., Adegbola, S., & Vermeire, S. (2022). Treat-to-target strategies in inflammatory bowel disease. *Lancet Gastroenterology & Hepatology*.
- Khor, B., Gardet, A., & Xavier, R. J. (2011). Genetics and pathogenesis of inflammatory bowel disease. *Nature*, 474(7351), 307–317. <https://doi.org/10.1038/nature10209>
- Sun, X., Li, Y., Wang, H., et al. (2025). Research status and trends of gut microbiota and intestinal diseases: A bibliometric analysis. *Frontiers in Cellular and Infection Microbiology*.
- Li, H., Chen, Y., Zhang, X., et al. (2025). Mapping the evolution of IBD treatment: A bibliometric analysis of biologics and small molecules. *Pharmaceuticals*, 18(3), 312. <https://doi.org/10.3390/ph18030312>
- Wang, S. R., et al. (2025). A bibliometric analysis of global research status and trends on gut microbiota metabolites in irritable bowel syndrome. *Frontiers in Microbiology*.
- Zhang, R., et al. (2025). Bibliometric analysis of sepsis and gut microbiota. *Frontiers in Microbiology*.